Horizon Discovery Group, a Cambridge-based biotech backed by DFJ Esprit and Roche Venture Fund among others, is planning to raise £25m in its IPO on the AIM segment of the London Stock Exchange.
Company plans to open offices in New York and Los Angeles, and launch a new SaaS product
Bridges drew equity from its Evergreen fund, which held a final close on £50m in July 2018
Fund targets European companies operating in the consumer, industrial and healthcare services sectors
GP launched a small-cap strategy in Q3 to back companies of the size of ID Systemes